Heron Therapeutics, Inc.
HRTX· Nasdaq
HRTXHeron Therapeutics, Inc.
Filed Mar 29, 2023 · 10-K · 88 days after period end · 0000950170-23-010603
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $30.03M | $20.66M | $20.61M | $35.08M |
| Net Income | -$19.87M | -$54.65M | -$62.28M | -$57.92M |
| EPS Diluted | — | — | -$0.68 | -$0.65 |
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 29, 2023 · 88 d after period end
